To include your compound in the COVID-19 Resource Center, submit it here.

Product Development
First Phase III data for an IL-6 mAb in COVID-19 disappoint

A Phase III miss for IL-6 inhibitor Kevzara may not reflect a broader problem with the target or the strengthening theory that immune modulators are the best line of defense ...

FDA’s pediatric anti-infective guidance encourages efficacy extrapolation, adolescent inclusion in adult pivotal trials

FDA’s latest pediatric guidance outlines what’s needed to extrapolate efficacy of anti-infective drugs from adults to children, and sends a clear message that adult trials should ...

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

Novartis to pay $678M in kickbacks settlement
Novartis AG (NYSE:NVS; SIX:NOVN) will pay $678 million and, under a corporate integrity agreement, conduct its ...

On heels of $100M raise, Annexon joins burgeoning IPO queue

Two days after raising $100 million in a series D round heavy with crossover investors, Annexon has filed to go public on NASDAQ.

The filing adds to a ...

Building on ALS results, Amylyx raises $30M ahead of Alzheimer’s readout

Roughly six months after a placebo-controlled study showed that Amylyx’s lead product slowed disease progression in patients with ALS, the company has closed a $30 million series B ...

Translation in Brief
Tesla developing RNA therapeutic ‘microfactories’ for CureVac, plus CRISPR-directed RNA epigenetic modifications and Nucleix

Tesla ‘microfactories’ for CureVac

Elon Musk tweeted on Wednesday that Tesla Grohmann Automation GmbH unit of Tesla Inc. (NASDAQ:TSLA) is ...

Management Tracks
Angus Grant joins BeiGene as CFO; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and moreBy Robin Sawka, BioCentury Staff

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery ...

BioCentury ISSN 1097-7201